Fibroblast growth factor 23 and incident CKD in type 2 diabetes

Tamara Isakova, Timothy E. Craven, Jungwha Lee, Julia J. Scialla, Huiliang Xie, Patricia Wahl, Santica M. Marcovina, Robert P. Byington, Myles Wolf

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and objectives High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. Design, setting, participants, & measurements A prospective case-cohort study was conducted within the Action to Control Cardiovascular Risk in Diabetes Trial. The analytic sample consisted of a random subcohort of 590 patients with type 2 diabetes without prevalent CKD at baseline, 124 of whom developed incident CKD during follow-up, and 520 additional patients with incident CKD outside the random subcohort. The association between serum intact fibroblast growth factor 23 and incident CKD, defined as the new onset of eGFR˂60 ml/min per 1.73m2 that represented a≥25%decrease frombaseline in an individualwith eGFR≥60 ml/min per 1.73m2 and no microalbuminuria (˂30 mg/g creatinine) at baseline, was tested. Results The mean baseline eGFR in the random subcohort was 90.9±22.7 ml/min per 1.73 m2. During a median follow-up of 4.7 years, therewas a total of 644 patientswith incident CKD. The median baseline fibroblast growth factor 23 level was modestly higher among patients with incident CKD versus controls (43.5, interquartile range=34.7–55.1 versus 39.8, interquartile range=31.9–49.5 pg/ml; P˂0.001). Higher baseline fibroblast growth factor 23 levels were associated with higher risk of incident CKD in unadjusted and demographics-adjusted models, but the effect was attenuated after additional adjustment for clinical risk factors and baseline eGFR (hazard ratio per SD of natural log fibroblast growth factor 23, 1.09; 95% confidence interval, 0.94 to 1.27), which was the strongest predictor of incident CKD. Consistent with the results of primary analyses, baseline fibroblast growth factor 23 was not associated with eGFR slope. Conclusions Higher fibroblast growth factor 23 levels are not independently associated with higher risk of incident CKD in patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume10
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Type 2 Diabetes Mellitus
fibroblast growth factor 23
Creatinine
Cohort Studies
Demography
Confidence Intervals
Serum

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Isakova, T., Craven, T. E., Lee, J., Scialla, J. J., Xie, H., Wahl, P., ... Wolf, M. (2015). Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Clinical Journal of the American Society of Nephrology, 10(1), 29-38. https://doi.org/10.2215/CJN.06190614

Fibroblast growth factor 23 and incident CKD in type 2 diabetes. / Isakova, Tamara; Craven, Timothy E.; Lee, Jungwha; Scialla, Julia J.; Xie, Huiliang; Wahl, Patricia; Marcovina, Santica M.; Byington, Robert P.; Wolf, Myles.

In: Clinical Journal of the American Society of Nephrology, Vol. 10, No. 1, 2015, p. 29-38.

Research output: Contribution to journalArticle

Isakova, T, Craven, TE, Lee, J, Scialla, JJ, Xie, H, Wahl, P, Marcovina, SM, Byington, RP & Wolf, M 2015, 'Fibroblast growth factor 23 and incident CKD in type 2 diabetes', Clinical Journal of the American Society of Nephrology, vol. 10, no. 1, pp. 29-38. https://doi.org/10.2215/CJN.06190614
Isakova, Tamara ; Craven, Timothy E. ; Lee, Jungwha ; Scialla, Julia J. ; Xie, Huiliang ; Wahl, Patricia ; Marcovina, Santica M. ; Byington, Robert P. ; Wolf, Myles. / Fibroblast growth factor 23 and incident CKD in type 2 diabetes. In: Clinical Journal of the American Society of Nephrology. 2015 ; Vol. 10, No. 1. pp. 29-38.
@article{ada55dc9ed8f4e3da1b67542321e5d90,
title = "Fibroblast growth factor 23 and incident CKD in type 2 diabetes",
abstract = "Background and objectives High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. Design, setting, participants, & measurements A prospective case-cohort study was conducted within the Action to Control Cardiovascular Risk in Diabetes Trial. The analytic sample consisted of a random subcohort of 590 patients with type 2 diabetes without prevalent CKD at baseline, 124 of whom developed incident CKD during follow-up, and 520 additional patients with incident CKD outside the random subcohort. The association between serum intact fibroblast growth factor 23 and incident CKD, defined as the new onset of eGFR˂60 ml/min per 1.73m2 that represented a≥25{\%}decrease frombaseline in an individualwith eGFR≥60 ml/min per 1.73m2 and no microalbuminuria (˂30 mg/g creatinine) at baseline, was tested. Results The mean baseline eGFR in the random subcohort was 90.9±22.7 ml/min per 1.73 m2. During a median follow-up of 4.7 years, therewas a total of 644 patientswith incident CKD. The median baseline fibroblast growth factor 23 level was modestly higher among patients with incident CKD versus controls (43.5, interquartile range=34.7–55.1 versus 39.8, interquartile range=31.9–49.5 pg/ml; P˂0.001). Higher baseline fibroblast growth factor 23 levels were associated with higher risk of incident CKD in unadjusted and demographics-adjusted models, but the effect was attenuated after additional adjustment for clinical risk factors and baseline eGFR (hazard ratio per SD of natural log fibroblast growth factor 23, 1.09; 95{\%} confidence interval, 0.94 to 1.27), which was the strongest predictor of incident CKD. Consistent with the results of primary analyses, baseline fibroblast growth factor 23 was not associated with eGFR slope. Conclusions Higher fibroblast growth factor 23 levels are not independently associated with higher risk of incident CKD in patients with type 2 diabetes.",
author = "Tamara Isakova and Craven, {Timothy E.} and Jungwha Lee and Scialla, {Julia J.} and Huiliang Xie and Patricia Wahl and Marcovina, {Santica M.} and Byington, {Robert P.} and Myles Wolf",
year = "2015",
doi = "10.2215/CJN.06190614",
language = "English",
volume = "10",
pages = "29--38",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Fibroblast growth factor 23 and incident CKD in type 2 diabetes

AU - Isakova, Tamara

AU - Craven, Timothy E.

AU - Lee, Jungwha

AU - Scialla, Julia J.

AU - Xie, Huiliang

AU - Wahl, Patricia

AU - Marcovina, Santica M.

AU - Byington, Robert P.

AU - Wolf, Myles

PY - 2015

Y1 - 2015

N2 - Background and objectives High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. Design, setting, participants, & measurements A prospective case-cohort study was conducted within the Action to Control Cardiovascular Risk in Diabetes Trial. The analytic sample consisted of a random subcohort of 590 patients with type 2 diabetes without prevalent CKD at baseline, 124 of whom developed incident CKD during follow-up, and 520 additional patients with incident CKD outside the random subcohort. The association between serum intact fibroblast growth factor 23 and incident CKD, defined as the new onset of eGFR˂60 ml/min per 1.73m2 that represented a≥25%decrease frombaseline in an individualwith eGFR≥60 ml/min per 1.73m2 and no microalbuminuria (˂30 mg/g creatinine) at baseline, was tested. Results The mean baseline eGFR in the random subcohort was 90.9±22.7 ml/min per 1.73 m2. During a median follow-up of 4.7 years, therewas a total of 644 patientswith incident CKD. The median baseline fibroblast growth factor 23 level was modestly higher among patients with incident CKD versus controls (43.5, interquartile range=34.7–55.1 versus 39.8, interquartile range=31.9–49.5 pg/ml; P˂0.001). Higher baseline fibroblast growth factor 23 levels were associated with higher risk of incident CKD in unadjusted and demographics-adjusted models, but the effect was attenuated after additional adjustment for clinical risk factors and baseline eGFR (hazard ratio per SD of natural log fibroblast growth factor 23, 1.09; 95% confidence interval, 0.94 to 1.27), which was the strongest predictor of incident CKD. Consistent with the results of primary analyses, baseline fibroblast growth factor 23 was not associated with eGFR slope. Conclusions Higher fibroblast growth factor 23 levels are not independently associated with higher risk of incident CKD in patients with type 2 diabetes.

AB - Background and objectives High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. Design, setting, participants, & measurements A prospective case-cohort study was conducted within the Action to Control Cardiovascular Risk in Diabetes Trial. The analytic sample consisted of a random subcohort of 590 patients with type 2 diabetes without prevalent CKD at baseline, 124 of whom developed incident CKD during follow-up, and 520 additional patients with incident CKD outside the random subcohort. The association between serum intact fibroblast growth factor 23 and incident CKD, defined as the new onset of eGFR˂60 ml/min per 1.73m2 that represented a≥25%decrease frombaseline in an individualwith eGFR≥60 ml/min per 1.73m2 and no microalbuminuria (˂30 mg/g creatinine) at baseline, was tested. Results The mean baseline eGFR in the random subcohort was 90.9±22.7 ml/min per 1.73 m2. During a median follow-up of 4.7 years, therewas a total of 644 patientswith incident CKD. The median baseline fibroblast growth factor 23 level was modestly higher among patients with incident CKD versus controls (43.5, interquartile range=34.7–55.1 versus 39.8, interquartile range=31.9–49.5 pg/ml; P˂0.001). Higher baseline fibroblast growth factor 23 levels were associated with higher risk of incident CKD in unadjusted and demographics-adjusted models, but the effect was attenuated after additional adjustment for clinical risk factors and baseline eGFR (hazard ratio per SD of natural log fibroblast growth factor 23, 1.09; 95% confidence interval, 0.94 to 1.27), which was the strongest predictor of incident CKD. Consistent with the results of primary analyses, baseline fibroblast growth factor 23 was not associated with eGFR slope. Conclusions Higher fibroblast growth factor 23 levels are not independently associated with higher risk of incident CKD in patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84923916544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923916544&partnerID=8YFLogxK

U2 - 10.2215/CJN.06190614

DO - 10.2215/CJN.06190614

M3 - Article

AN - SCOPUS:84923916544

VL - 10

SP - 29

EP - 38

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 1

ER -